Choose your language

Keynote Presentations

Gregory L. Verdine, Ph.D.
Erving Professor of Chemistry
Harvard University

John Maraganore, Ph.D.
Chief Executive Officer
Alnylam Pharmaceuticals, Inc.

Claes R. Wahlestedt, M.D., Ph.D.
Professor, Director of Neuroscience Discovery
The Scripps Research Institute - Florida

TIDES® continues to be the must-attend event for the industry as it grows in attendance each year.

Program highlights include:

• CBER, FDA and 3 European regulatory agency speakers describe current expectations for quality and safety for approval of oligonucleotide and peptide therapeutics and vaccines
• New dual tracks on CMC let you benchmark your company against industry leaders in manufacturing and analysis of API
• Advances in formulation and delivery offer the latest updates for market expansion opportunities
• Expanded break-out discussion sessions give you uncensored insights into the industry's most pressing challenges
• Learn new skills and expand your knowledge with 5 cutting-edge pre-conference courses on the core disciplines of discovering, developing and manufacturing oligonucleotide and peptide-based therapeutics

Back by popular demand, expanded break-out discussion sessions and pre-conference courses give you the opportunity to gain behind-the-scenes insight into critical industry issues, and to ask your specific questions to the experts in a small group setting.

TIDES® is now the most comprehensive industry event with the addition of the 2nd Annual Oligonucleotide Therapeutics Discovery conference at the same venue

Co-Located Conferences
IBC's 6th International Applications of Nucleic Acids Technologies in Molecular Diagnostics Accelerating Product Development through Cutting Edge Regulatory,Business and Technology Strategies	IBC's 2nd Annual Oligonucleotide Therapeutics Discovery For Discovery, Preclinical and Early Development Scientists
April 27-28, 2010	April 26-28, 2010
Keynote Presentations Elizabeth Mansfield, Ph.D. Director for Personalized Medicine, OIVD CDRH, US FDA William Pignato Global Head, Regulatory Affairs Novartis Molecular Diagnostics	Preclinical chemical modifications to improve drug-like properties Overcoming cellular barriers to siRNA delivery Nonclinical safety assessment strategies 13 preclinical and clinical case studies Techniques for oligo lead discovery and candidate selection
3-Day registration options provide access to all sessions and materials